The mechanisms of antinuclear antibody production and its pathogenicity in systemic autoimmune diseases

Japanese Journal of Clinical Immunology

Volumn 29, Issue 2, 2006, Pages 57-64

  Fujii, Takao ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Antinuclear antibodies; Autoreactive T cells; MRL lpr mice; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY;

ANIMAL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOSYNTHESIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; PROGNOSIS; T-LYMPHOCYTES;

EID: 33745125405     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.29.57     Document Type: Article

References (42)

1. Hargraves MM, Richmond BS, Morton R: Presentation of two bone marrow elements: The “tart” cell and the “L.E.” cell. Proc Mayo Clin 23: 25–28, 1948.
2. Tan EM: Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44: 93–151, 1989.
3. Sclomchik, MJ, Craft J, Mamula MJ: From T to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol 1: 147–153, 2001.
4. Craft J, Peng S, Fujii T, et al.: Autoreactive T cells in murine lupus. Immunological Res 19: 245–257, 1999.
5. Peng SL, Madaio MP, Hayday AC, et al.: Propagation and regulation of systemic autoimmunity by γδT cells. J Immunol 157: 5689–5698, 1996.
6. Peng SL, Madaio MP, Hughes DPM, et al.: Murine lupus in the absence of αβ T cells. J Immunol 156: 4041–4049, 1996.
7. Peng SL, Fatenejad S, Craft J: Induction of nonpathogenic, humoral autoimmunity in lupus-prone mice by a class II-restricted, transgenic αβ T cell. Separation of autoantigen-specific and -nonspecific help. J Immunol 157: 5225–5230, 1996.
8. Ma J, Xu J, Madaio MP, et al.: Autoimmune lpr/lpr mice deficient in CD40 ligand. Spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 157: 417–426, 1996.
9. Early GS, Zhao W, Burns CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice. Response correlates with the absence of an anti-antibody response. J Immunol 157: 3159–3164, 1996.
10. Yan J, Mamula MJ: B and T cell tolerance and autoimmunity in autoantibody transgenic mice. Int Immunol 14: 963–971, 2002.
11. Crispin JC, Martinez A, Alcocer-Varela, J: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21: 273–276, 2003.
12. Lin R.-H., Mamula MJ, Hardin JA, etal.: Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med 173: 1433–1439, 1991.
13. + T cells from lupus-prone mice are hypertensive to T cell receptor engagement with low and high affinity peptide antigens: A model to explain spontaneous T cell activation in lupus. J Exp Med 193: 329–337, 2001.
14. − T cells show reduced sensitivity to suppression by CD4+, CD25 + regulatory T cells in vitro. A novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum 52: 1180–1184, 2005.
15. Higuchi T, Aiba Y, Nomura T, et al.: Cutting edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 168: 9–12, 2002.
16. Dasai-Mehta A, Lu L, Ramsey-Goldman, R, et al.: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97: 2063–2073, 1996.
17. Koshy M, Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98: 826–837, 1996.
18. Grimaldi CM, Hicks R, Diamond B: B cell selection and susceptibility to autoimmunity. J Immunol 174: 1775–1781, 2005.
19. Sikakis PP, Boletis JN, Lionaki S, et al.: Remission of proliferative lupus nephritis following B cell depletion therapy is proceeded by down-regulation of T cell costimulatory molecule CD40 ligand. An open-labeled trail. Arthritis Rheum 52: 501–513, 2005.
20. Anolik JH, Barnard J, Cappione A, et al.: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580–3590, 2004.
21. Yurasov S, Wardemann H, Hammersen J, et al.: Defective B cell tolerance checkpoints in systemic lupus erythemtosus. J Exp Med 201: 703–711, 2005.
22. Harn BH: Antibodies to DNA. N Engl J Med 338: 1359–1368, 1998.
23. Christensen SR, Kashgarian M, Alexopoulou L, et al.: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202: 321–331, 2005.
24. Wu X, Peng SL: Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 54: 336–342, 2006.
25. Anders H-J, Vielhauer V, Eis V, et al.: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas (1pr) mice. FASEB J 18: 534–536, 2004.
26. Chan OTM, Hannum LG, Haberman AM, et al.: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189: 1639–1647, 1999.
27. Izui S, Kelly VE, Masuda K, et al.: Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 133: 227–233, 1984.
28. Bijl N, Dijstelbloem HM, Oost WW, et al.: IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology 41: 62–67, 2002.
29. Singh RR, Ebling FM, Sercarz EE, et al.: Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 96: 2990–2996, 1995.
30. Waisman A, Ruiz PJ, Israeli E, et al.: Modulation of murine systemic lupus erythematosus with peptides based on complimentarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci USA 94: 4620–4625, 1997.
31. Gaynor B, Putterman C, Valadon P, et al.: Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci USA 94: 1955–1960, 1997.
32. Kaliyaperumal A, Michaeles MA, Datta SK: Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162: 5775–5783, 1999.
33. Jouanne C, Avrameas S, Payelle-Brogard B: A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZB x NZW) F1 mice. Imunology 96: 333–339, 1999.
34. Eilat E, Dayan M, Zinger H, et al.: The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 98: 1148–1153, 2001.
35. Harn BH, Singh RR, Wong WK, et al.: Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 44: 432–441, 2001.
36. Marino M, Ruvo M, De Falco S, et al.: Prevention of systemic lupus erythematosus in MRL/ lpr mice by administration of an immunoglobulin-binding peptide. Nat Biotechnol 18: 735–739, 2000.
37. Fujio K, Okamoto A, Tahara H, et al.: Nuceleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J Immunol 173: 2118–2125, 2004.
38. Singh RR: The potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr Opin Rheumatol 12: 399–406, 2000.
39. Homma M, Mimori T, Takeda Y, et al.: Autoantibodies to the Sm antigen: Immunological approach to clinical aspects of systemic lupus erythematosus. J Rheumatol 14: 188–193, 1987.
40. Yasuma M, Takasaki Y, Matsumoto K, et al.: Clinical signiicance of IgG anti-Sm antibodies in patients with systemic lupus erythematosus. J Rheumatol 17: 469–475, 1990.
41. Okada J, Hamana T, Kondo H: Anti-U1RNP antibody and aseptic meningitis in connective tissue diseases. Scand J Rheumatol 32: 247–252, 2003.
42. Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526–1533, 2003.